Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Colman

Showing results (91-100 of 155) with videos related to

Pageof 16
Sort By:
The Journal of Nutrition|May 21, 2026
Identification of circulating lipidomic biomarkers of malnutrition risk among oncology patients in the Total Cancer Care (TCC) Study: a cross-sectional analysisRachel Hoobler, J Alan Maschek, Bai Luo, et al.
Cell Reports|May 3, 2018
Mutant IDH1 Promotes Glioma Formation In VivoBeatrice Philip, Diana X Yu, Mark R Silvis, et al.
Cancers|October 28, 2023
The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint InhibitorsIslam Eljilany, Payman Ghasemi Saghand, James Chen, et al.
Neuro-Oncology|March 5, 2008
A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignanciesMorris D Groves, Michael J Glantz, Marc C Chamberlain, et al.
Neuro-Oncology|March 4, 2008
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiformeVinay K Puduvalli, Pierre Giglio, Morris D Groves, et al.
Neuro-Oncology|November 1, 2020
Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trialsBenjamin M Ellingson, Matthew S Brown, Jerrold L Boxerman, et al.
Journal of Neuro-Oncology|October 29, 2015
A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group studyH Ian Robins, Peixin Zhang, Mark R Gilbert, et al.
Neuro-Oncology|May 31, 2022
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trialMacarena I de la Fuente, Howard Colman, Mark Rosenthal, et al.
Neuro-Oncology|August 15, 2014
Clinical course and progression-free survival of adult intracranial and spinal ependymoma patientsElizabeth Vera-Bolanos, Kenneth Aldape, Ying Yuan, et al.
Journal of Oncology Research and Therapy|March 14, 2025
Differences in Co-Expression of T Cell Co-Inhibitory and Co-Stimulatory Molecules with PD-1 Across Different Human CancersAhmad A Tarhini, Dale Hedges, Aik Choon Tan, et al.
Pageof 16

Showing results (91-100 of 155) with videos related to

Sort By:
Pageof 16
The Journal of Nutrition|May 21, 2026
Identification of circulating lipidomic biomarkers of malnutrition risk among oncology patients in the Total Cancer Care (TCC) Study: a cross-sectional analysisRachel Hoobler, J Alan Maschek, Bai Luo, et al.
Cell Reports|May 3, 2018
Mutant IDH1 Promotes Glioma Formation In VivoBeatrice Philip, Diana X Yu, Mark R Silvis, et al.
Cancers|October 28, 2023
The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint InhibitorsIslam Eljilany, Payman Ghasemi Saghand, James Chen, et al.
Neuro-Oncology|March 5, 2008
A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignanciesMorris D Groves, Michael J Glantz, Marc C Chamberlain, et al.
Neuro-Oncology|March 4, 2008
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiformeVinay K Puduvalli, Pierre Giglio, Morris D Groves, et al.
Neuro-Oncology|November 1, 2020
Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trialsBenjamin M Ellingson, Matthew S Brown, Jerrold L Boxerman, et al.
Journal of Neuro-Oncology|October 29, 2015
A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group studyH Ian Robins, Peixin Zhang, Mark R Gilbert, et al.
Neuro-Oncology|May 31, 2022
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trialMacarena I de la Fuente, Howard Colman, Mark Rosenthal, et al.
Neuro-Oncology|August 15, 2014
Clinical course and progression-free survival of adult intracranial and spinal ependymoma patientsElizabeth Vera-Bolanos, Kenneth Aldape, Ying Yuan, et al.
Journal of Oncology Research and Therapy|March 14, 2025
Differences in Co-Expression of T Cell Co-Inhibitory and Co-Stimulatory Molecules with PD-1 Across Different Human CancersAhmad A Tarhini, Dale Hedges, Aik Choon Tan, et al.
Pageof 16